Stereotactic radiosurgery (SRS) serves as a mainstay for intracranial oligometastases. However, clinicians often face difficult diagnostic and clinical dilemmas when lesions enlarge after radiosurgery. Specifically, distinguishing recurrent tumor from radiation necrosis remains challenging on conventional neuroimaging. To resolve this therapeutic challenge, laser interstitial thermal therapy (LITT) has emerged as an effective minimally invasive cytoreductive technique. A comprehensive systematic review and meta-analysis evaluated the safety, local tumor control, and therapeutic synergy of LITT for brain metastases. This pooled analysis evaluated thirty clinical studies encompassing 972 patients, establishing critical benchmarks for multidisciplinary neuro-oncology teams.

Clinical Challenges: Differentiating Radiation Necrosis from Recurrence

The widespread use of high-dose stereotactic radiosurgery has fundamentally transformed intracranial metastasis management. Consequently, clinicians encounter post-radiation tissue changes with increasing frequency. Distinguishing true tumor recurrence from treatment-induced radiation necrosis presents a major diagnostic hurdle. Both conditions exhibit expanding contrast enhancement and substantial perilesional vasogenic edema on magnetic resonance imaging. Therefore, patients often receive prolonged empiric corticosteroid therapy, causing significant metabolic and immunological toxicities. Alternatively, open craniotomy carries notable perioperative morbidity, prolonged recovery times, and functional risks in fragile cancer patients. Minimally invasive thermal ablation overcomes these obstacles by enabling stereotactic biopsy and simultaneous hyperthermic cytoreduction through a single burr hole. Consequently, surgeons can obtain definitive histopathology while immediately coagulating the offending lesion. This dual approach eliminates diagnostic ambiguity and achieves rapid local disease stabilization. Furthermore, the minimally invasive technique preserves functional performance and enables patients to resume vital systemic oncological treatments without surgical delay.

Evaluating Local Tumor Control with LITT for Brain Metastases

The pooled meta-analysis provides compelling evidence supporting the efficacy of LITT for brain metastases. Among patients receiving thermal ablation monotherapy, the pooled six-month local tumor control rate reached 74.4%. Moreover, the pooled twelve-month local tumor control rate remained durable at 67.9%. When researchers stratified outcomes by underlying histology, local control rates remained remarkably consistent. Lesions with confirmed metastatic recurrence achieved local control rates of 74.0% at six months and 67.9% at twelve months. Similarly, lesions demonstrating radiation necrosis achieved six-month and twelve-month control rates of 76.6% and 65.7%, respectively. These robust figures demonstrate that thermal ablation reliably stabilizes expanding intracranial lesions and halts progressive neurological decline. Real-time thermal coagulation destroys radioresistant neoplastic clones and disrupts dysfunctional vascular networks. Consequently, these findings validate thermal ablation as an effective salvage modality following radiosurgical failure. Furthermore, the durability of local control matches open surgical resection while delivering significantly lower procedural morbidity.

Multimodal Synergy: Combining LITT with Radiotherapy and Immunotherapy

Although thermal ablation monotherapy delivers dependable local control, emerging multimodal regimens offer even greater therapeutic promise. The meta-analysis demonstrated substantial improvements when clinicians combined thermal ablation with targeted adjuvant therapies. Specifically, combining thermal ablation with stereotactic radiotherapy achieved a 76% local control rate. Furthermore, combining ablation with immune checkpoint blockade increased twelve-month local control to 94.7%. Most remarkably, combining thermal ablation with consolidation stereotactic radiosurgery yielded a 100% twelve-month local control rate across analyzed cohorts. Biologically, thermal hyperthermia transiently disrupts the peritumoral blood-brain barrier. This enhanced permeability facilitates deeper intracranial penetration of systemic immunotherapies and targeted molecules. Additionally, thermal coagulative necrosis releases abundant tumor-specific neoantigens into the surrounding microenvironment. This immunogenic response stimulates dendritic cell recruitment and activates cytotoxic T lymphocytes. Therefore, thermal ablation acts not only as a local cytoreductive tool but also as a potent immunomodulatory catalyst.

Safety Profile, Adverse Events, and Procedural Complications

Safety remains paramount when managing recurrent secondary intracranial neoplasms and radiation necrosis. The pooled findings confirm that thermal ablation maintains an acceptable safety profile across diverse clinical settings. Transient neurological deficits occurred most frequently, reflecting temporary post-ablation perilesional edema and inflammatory reactions. Fortunately, clinicians successfully managed these self-limiting symptoms with short corticosteroid tapers or hyperosmolar therapy. In contrast, permanent neurological deficits developed infrequently, demonstrating the high precision of real-time MR thermography guidance. Across thirty studies comprising 972 patients, procedure-related complications occurred in only twenty patients. Reported complications primarily included localized intracranial hemorrhage, probe malposition, superficial wound infections, and persistent symptomatic edema. Compared with conventional open craniotomy, patients undergoing thermal ablation experience significantly shorter hospital stays, minimal blood loss, and reduced intensive care requirements. Consequently, thermal ablation provides a safe and well-tolerated surgical alternative for deep-seated or surgically challenging intracranial lesions.

Key Predictors of Optimal Treatment Outcomes and Patient Selection

Identifying clinical and radiological predictors is essential for optimizing candidate selection and procedural outcomes. The systematic review identified four significant factors associated with superior local disease control. First, achieving a greater extent of thermal ablation strongly correlated with improved long-term progression-free survival. Complete thermal coverage of the enhancing margin significantly reduced marginal tumor recurrence. Second, smaller pre-treatment tumor volume strongly predicted favorable local control, as larger lesions present technical ablation boundaries. Third, histopathological confirmation of pure radiation necrosis correlated with better local stability compared to active recurrent malignancy. Finally, administering systemic chemotherapy or targeted therapies following ablation significantly prolonged local tumor control. Consequently, neuro-oncology teams should prioritize thermal ablation for patients with well-demarcated, small-to-moderate lesions amenable to complete ablation. Additionally, prompt administration of post-procedural systemic therapy consolidates local success and prevents distant intracranial progression.

Translating Evidence into Clinical Practice: Neurosurgical Implications

The pooled evidence firmly establishes thermal ablation within modern neuro-oncological management algorithms. Historically, patients with radiosurgical failures faced limited options, often restricted to high-risk craniotomies or supportive care. Today, thermal ablation offers a minimally invasive salvage option that successfully bridges surgical and radiation disciplines. However, clinicians must interpret the current evidence base within its proper methodological framework. Because most available data originate from retrospective observational cohorts, considerable clinical heterogeneity exists across centers. Variations in laser platforms, thermometry monitoring parameters, and institutional protocols underscore the need for prospective clinical trials. Future multicenter investigations will refine patient selection criteria, standardize thermal dosing protocols, and define optimal combination regimens. In routine neurosurgical practice, multidisciplinary tumor boards should collaboratively assess eligible candidates. By integrating MR thermography, histopathological confirmation, and systemic therapies, clinicians can maximize local disease control while preserving neurological function and quality of life.

What is the primary mechanism of action of LITT for brain metastases?

Laser interstitial thermal therapy delivers focused laser light through a stereotactically placed fiberoptic probe. The light converts into thermal energy within the target lesion, inducing coagulative necrosis. Real-time magnetic resonance thermometry continuously monitors tissue temperatures, destroying tumor cells while protecting surrounding critical brain structures.

How effective is LITT in treating post-radiation cerebral necrosis?

Thermal ablation demonstrates high efficacy for radiation necrosis. The pooled meta-analysis revealed local control rates of 76.6% at six months and 65.7% at twelve months. Thermal coagulative energy inactivates necrotic inflammatory tissue, which effectively reduces perilesional edema and facilitates successful corticosteroid tapering in symptomatic patients.

Why does combining LITT with immunotherapy improve local tumor control?

Thermal ablation induces immunogenic cell death, releasing tumor neoantigens and inflammatory cytokines into the microenvironment. Furthermore, hyperthermia transiently opens the blood-brain barrier surrounding the lesion. This enhanced vascular permeability allows immune checkpoint inhibitors to penetrate intracranial targets effectively, generating twelve-month local control rates exceeding 94%.

Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Mizutani Y et al. Laser interstitial thermal therapy (LITT) for brain metastases: a systematic review and pooled analysis of Efficacy/Safety and the role of combination treatments. J Neurooncol. 2026 Jun 09. doi: 10.1007/s11060-026-05645-w. PMID: 42265512.


2. Bastos DC, Rao G, Oliva ICG, et al. Predictors of Local Control of Brain Metastasis Treated with Laser Interstitial Thermal Therapy. Neurosurgery. 2020;87(1):112-122. doi:10.1093/neuros/nyz357.


3. Sloan AE, Barnett GH, Brewer C, et al. Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study. JCO Precis Oncol. 2026;10:e2500412. doi:10.1200/PO.25.00412.